← Home
GlaxoSmithKline 
Pharma / Pharma and biotechnology
Press Releases
| Date | Press release |
|---|---|
| 2025-04-30 09:41:00 | Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | Gsk Leads Cervarix Market Amid Global Vaccination Efforts The cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. key drivers include rising hpv awareness, vaccination rates, and global immunization programs. gsk plc leads the market, with cervarix targeting hpv-linked conditions like cervical cancer. advanced hpv vaccines and personalized immunization strategies are emerging trends. the report details market dynamics, historical data, and future growth projections. the cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. key drivers include rising hpv awareness, vaccination rates, and global immunization programs. gsk plc leads the market, with cervarix targeting hpv-linked conditions like cervical cancer. advanced hpv vaccines and personalized immunization strategies are emerging trends. the report details market dynamics, historical data, and future growth projections. |
| 2025-04-17 08:00:00 | Alector Announces Completion Of Enrollment In The Progress-ad Phase 2 Clinical Trial Of Al101/gsk4527226 In Individuals With Early Alzheimer’s Disease --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --enrollment completed ahead of schedule-- south san francisco, calif., april 17, 2025 (globe newswire) -- alector, inc. (nasdaq: alec), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in progress-ad, a 76-week phase 2 clinical trial evaluating the safety and efficacy of al101/gsk4527226 in slowing disease progression in individuals with early alzheimer’s disease (ad). |
| 2025-04-16 17:36:00 | Arexvy Recommended For Adults Aged 50-59 At Increased Risk For Severe Respiratory Syncytial Virus (rsv) Disease By Us Advisory Committee On Immunization Practices Philadelphia--(business wire)-- #arexvy--arexvy recommended for adults aged 50-59 at increased risk for severe rsv disease by us advisory committee on immunization practices. |
| 2025-04-16 16:57:00 | Gsk’s 5-in-1 Meningococcal Vaccine Penmenvy Receives Positive Recommendation From Us Advisory Committee On Immunization Practices Philadelphia--(business wire)-- #adolescents--gsk’s 5-in-1 meningococcal vaccine penmenvy receives positive recommendation from us advisory committee on immunization practices. |
| 2025-04-08 07:00:00 | Gsk Investor Alert: Bronstein, Gewirtz And Grossman, Llc Announces That Bronstein, Gewirtz & Grossman, Llc Stockholders With Substantial Losses Have Opportunity To Lead Class Action Lawsuit! New york city, ny / access newswire / april 8, 2025 / bronstein, gewirtz & grossman, llc, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against gsk plc (\"gsk\" or \"the company\") (nyse:gsk) and certain of its officers. class definition this lawsuit seeks to recover damages against defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired gsk american depositary receipts (\"adrs\") between february 5, 2020 and august 14, 2022, both dates inclusive (the \"class period\"). |
| 2025-04-07 16:30:00 |
|
| 2025-04-07 16:00:00 |
|
| 2025-04-07 15:45:00 |
|
| 2025-04-07 13:30:00 |
|
| 2025-04-07 12:19:00 |
|
| 2025-04-07 11:00:00 |
|
| 2025-04-07 07:30:00 |
|
| 2025-04-07 07:00:00 |
|
| 2025-04-07 05:45:00 |
|
| 2025-04-07 03:00:00 |
|
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal